These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 28025814)

  • 21. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.
    Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS
    Int J Neuropsychopharmacol; 2021 Aug; 24(8):615-623. PubMed ID: 33987652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire.
    Hovmand OR; Madsen MK; Fisher PM; Stenbæk DS
    J Psychopharmacol; 2024 Oct; 38(10):924-932. PubMed ID: 39135498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
    Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
    Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimensions of consciousness and the psychedelic state.
    Bayne T; Carter O
    Neurosci Conscious; 2018; 2018(1):niy008. PubMed ID: 30254752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What can neuroscience tell us about the potential of psychedelics in healthcare? How the neurophenomenology of psychedelics research could help us to flourish throughout our lives, as well as to enhance our dying.
    Mackenzie R
    Curr Drug Abuse Rev; 2014; 7(3):136-45. PubMed ID: 25563449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
    Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD
    Sci Rep; 2017 Apr; 7():46421. PubMed ID: 28422113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelics, Meditation, and Self-Consciousness.
    Millière R; Carhart-Harris RL; Roseman L; Trautwein FM; Berkovich-Ohana A
    Front Psychol; 2018; 9():1475. PubMed ID: 30245648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
    Smigielski L; Scheidegger M; Kometer M; Vollenweider FX
    Neuroimage; 2019 Aug; 196():207-215. PubMed ID: 30965131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism.
    van Mulukom V; Patterson RE; van Elk M
    Psychopharmacology (Berl); 2020 Sep; 237(9):2725-2737. PubMed ID: 32472162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
    Raj P; Rauniyar S; Sapkale B
    Cureus; 2023 Nov; 15(11):e48719. PubMed ID: 38094517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.